Optivia Biotechnology has secured a $1.8m two-year Phase II small business innovation research (SBIR) grant, from the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH). The federal grant is expected to ...
The Israeli Ministry of Health (IMH) has approved Pluristem Therapeutics’ request to start a Phase II trial using its PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC). IC is a subset of peripheral ...
Tags: clinical study, Medicine
Wison Engineering Services Co. Ltd., announced that Wison Engineering Ltd., an indirect non-wholly owned subsidiary of the Group, has been awarded a contract for the engineering of Erdos Jinchengtai Coal-to-methanol Project (Phase II) for ...
Tags: Wison Bags, Textile
Cornerstone Pharmaceuticals has received the US Food and Drug Administration (FDA) orphan drug designation for its altered energy metabolism directed (AEMD) drug candidate 'CPI-613' for treatment of myelodysplastic syndrome (MDS). MDS is ...
Biopharmaceutical company Trigemina will deliver clinical data on its drug candidate TI-001 for the treatment of chronic migraine at the ongoing 7th Annual Pain Therapeutics Summit East in Boston, Massachusetts. The presentation will ...
Tags: Migraine Drug, Medicine
The US Food & Drug Administration (cof Orphan Product Development has granted orphan drug designation for Lumena Pharmaceuticals' LUM001 clinical program. Lumena obtained orphan designation for LUM001 in four rare cholestatic liver ...
Tags: Orphan Drug, Rare Liver Diseases
The US Patent & Trademark Office (USPTO) has issued a notice of allowance for Elorac's patent application regarding novel acne therapy. The US patent is entitled "Method and Composition for Treating Nodulocystic and Conglobate Acne ...
Tags: Acne Therapy, Medicine
Adaptive Biotechnologies, a biotechnology company, has secured a $2.5m Phase II small business innovation research (SBIR) award from the National Heart, Lung, and Blood Institute, a division of the NIH. The award is granted to ...
Tags: Adaptive Biotechnologies, Medicine
Can-Fite BioPharma, the parent company of OphthaliX, received a patent entitled ‘Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren’s syndrome’ from the European Patent Office. The ...
Tags: Can-Fite BioPharma
Newegg.com.com, the operation of US retail giant Newegg.com in the Chinese mainland, saw a phase-II R&D workshop engineering project break ground on September 3. The project, covering a land area of over 20,000 square meters and with ...
Tags: Newegg, webservice
PFM Medical, a developer and manufacturer of minimally invasive medical devices for cardio vascular technology, vascular access, surgery, and oncology, has received the US Food and Drug Administration (FDA) premarket approval for its ...
Tags: PFM Medical, Medicine
Solar photovoltaic (PV) demand from China and Japan during the second half of 2013 is forecast to reach 9GW, representing an increase of 100% compared to first-half 2013 and 70% compared to second-half 2012. Overall, PV demand from the Asia ...
Tags: PV Solar, Solar Industry
Philips Lighting, Rensselaer Polytechnic Institute and OSRAM are just a few of the key industry players who will look forward to the future of LED lighting at Smithers Apex's LEDs & the SSL Ecosystem 2013: Phase II the Path to Profit. The ...
Actavis Specialty Brands has purchased worldwide rights for Palau Pharma's Albaconazole antifungal agent indicated for the treatment of vulvo-vaginal candidiasis, onychomycosis and other antifungal applications. Possessing a ...
Australia- and Greer, S.C.-based specialty chemicals and solutions developer Alexium International Group Ltd. — holder of proprietary patent applications for Reactive Surface Treatment (RST) technology — has developed an ...